129 related articles for article (PubMed ID: 34254647)
1. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.
Zhu Y; Wang C; Li M; Yang X
J Pharm Pharmacol; 2021 Sep; 73(10):1418-1426. PubMed ID: 34254647
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.
Altman JK; Szilard A; Konicek BW; Iversen PW; Kroczynska B; Glaser H; Sassano A; Vakana E; Graff JR; Platanias LC
Blood; 2013 May; 121(18):3675-81. PubMed ID: 23509154
[TBL] [Abstract][Full Text] [Related]
7. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting MNK Selectively Targets Cervical Cancer via Suppressing eIF4E-Mediated β-Catenin Activation.
Zhang W; Su X; Li S; Wang Y; Wang Q; Zeng H
Am J Med Sci; 2019 Sep; 358(3):227-234. PubMed ID: 31327462
[TBL] [Abstract][Full Text] [Related]
9. MNK/eIF4E inhibition overcomes anlotinib resistance in non-small cell lung cancer.
Zhang Q; Li H; Li Q; Hu Q; Liu B
Fundam Clin Pharmacol; 2023 Apr; 37(2):245-252. PubMed ID: 36355605
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
11. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
[TBL] [Abstract][Full Text] [Related]
12. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
14. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.
Hu K; Zhang J; Yu M; Xiong C
Future Oncol; 2017 Mar; 13(6):489-498. PubMed ID: 27785922
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.
Liu S; Zha J; Lei M
Clin Transl Oncol; 2018 Mar; 20(3):374-381. PubMed ID: 28766096
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy.
Zhang Q; Zhao J; Xu T
Fundam Clin Pharmacol; 2023 Aug; 37(4):807-815. PubMed ID: 36691859
[TBL] [Abstract][Full Text] [Related]
20. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
